clinical trial · NCT05100069
Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer
Takeda·—·recruiting·n = 500
Non-small Cell Lung Cancer (NSCLC)Brigatinib
brief summary
This study is a survey in Japan of Brigatinib tablets used to treat Japanese people with non-small cell lung cancer. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects related to lung disease from Brigatinib. During the study, participants with non-small cell lung cancer will take Brigatinib tablets according to their clinic's standard practice. The study doctors will check for side effects from Brigatinib for 1 year.
started
Nov 1, 2021
primary completion
Sep 30, 2030
completion
Sep 30, 2030
last updated
Mar 17, 2026
official title
General Use-results Survey of Alunbrig Tablets "Non-small Cell Lung Cancer"
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol